Hello! Welcome to the discussion of the recent NEJM article by Jackson et al. on influenza vaccine effectiveness in the US during the 2015/2016 season. I am privileged to be a moderator for this conversation and to have the opportunity to gain some additional insights from the authors and our expert panel.
In this study, Jackson and colleagues used a test-negative study design with surveillance data from the Influenza Vaccine Effectiveness Network and found that overall influenza vaccine effectiveness against acute respiratory illness due to any laboratory-confirmed influenza virus was 48% in the 2015/2016 season. Importantly, the quadrivalent live attenuated vaccine (LAIV4) was not effective, including against influenza A(H1N1)pdm09, despite the fact that the LAIV4 product contained a slightly different influenza A(H1N1) strain (A/Bolivia/559/2013) than the one used in prior LAIV products. These results echo the findings of multiple studies from previous seasons that have found that LAIV4 is inferior to inactivated influenza vaccine (IIV).
To kick off the discussion, given the data added by this study, what are some of the reasons that LAIV4 might be less effective than IIV?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.